Loading...
Last submissions
-
-
-
-
Germán Reyes-Botero, Stéphanie Cartalat-Carel, Olivier Chinot, Maryline Barrie, Luc Taillandier, et al.. Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG). Oncologist, 2018, 23 (5), pp.524-e44. ⟨10.1634/theoncologist.2017-0689⟩. ⟨hal-01727451⟩
-
-
Ricardo Iván Martínez-Zamudio, Alketa Stefa, José Américo Nabuco Leva Ferreira Freitas, Themistoklis Vasilopoulos, Mark Simpson, et al.. Escape from oncogene-induced senescence is controlled by POU2F2 and memorized by chromatin scars. Cell Genomics, 2023, 3 (4), pp.100293. ⟨10.1016/j.xgen.2023.100293⟩. ⟨hal-04201593⟩
-
-
-
Stéphane Culine, Aude Fléchon, Gwenaelle Gravis, Guilhem Roubaud, Yohann Loriot, et al.. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study. Clinical Genitourinary Cancer, 2021, 19 (4), pp.e216-e222. ⟨10.1016/j.clgc.2021.02.005⟩. ⟨hal-03631553⟩
-
-
P. Pautier, A. Floquet, C. Chevreau, N. Penel, C. Guillemet, et al.. A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery. ESMO Open, 2021, 6 (4), pp.100209. ⟨10.1016/j.esmoop.2021.100209⟩. ⟨hal-03623631⟩
-
-
Jonathan Khalifa, Stéphane Supiot, Géraldine Pignot, Christophe Hennequin, Pierre Blanchard, et al.. Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder. Radiotherapy & Oncology, 2021, 161, pp.95-114. ⟨10.1016/j.radonc.2021.06.011⟩. ⟨hal-03612787⟩
-
-
Fabienne Bejjani, Emilie Evanno, Samantha Mahfoud, Claire Tolza, Kazem Zibara, et al.. Multiple Fra-1-bound enhancers showing different molecular and functional features can cooperate to repress gene transcription. Cell & Bioscience, 2023, 13 (1), pp.129. ⟨10.1186/s13578-023-01077-5⟩. ⟨hal-04170901⟩
-
Albert Braeuning, Patrick Balaguer, William Bourguet, Jordi Carreras-Puigvert, Katreece Feiertag, et al.. Development of new approach methods for the identification and characterization of endocrine metabolic disruptors—a PARC project. Frontiers in Toxicology, 2023, 5, pp.1212509. ⟨10.3389/ftox.2023.1212509⟩. ⟨hal-04167401⟩
-
Clémentine Garoche, Marina Grimaldi, Erwan Michelin, Abdelhay Boulahtouf, Anthony Marconi, et al.. Interlaboratory prevalidation of a new in vitro transcriptional activation assay for the screening of (anti-)androgenic activity of chemicals using the UALH-hAR cell line. Toxicology in Vitro, 2023, 88, pp.105554. ⟨10.1016/j.tiv.2023.105554⟩. ⟨ineris-04158325⟩
-
Pauline Marolleau, David Tougeron, Benoît ALLIGNET, Romain Cohen, David Sefrioui, et al.. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study. International Journal of Cancer, In press, ⟨10.1002/ijc.34636⟩. ⟨hal-04155601⟩
-
-
Eric van Cutsem, Erika Martinelli, Stefano Cascinu, Alberto Sobrero, Maria Banzi, et al.. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single‐Arm, Open‐Label Phase IIIb CONSIGN Study. Oncologist, 2019, 24 (2), pp.185-192. ⟨10.1634/theoncologist.2018-0072⟩. ⟨hal-02466428⟩